Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers.

Similar presentations


Presentation on theme: "Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers."— Presentation transcript:

1 Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers

2 Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers

3 Introduction In field practice, FMD vaccines are frequently administered to sheep at half the dose recommended for cattle Main reasons for this practice: i) a lower susceptibility of sheep to FMD infection ii) the relative vaccine cost as compared to the value of a sheep Study to compare vaccination of sheep with an AFTOVAXPUR DOE vaccine ᴑ 1 mL (half dose) ᴑ 2 mL (full dose) = registered claim

4 Study design Animals : 30 ewes, 1 year olds, Texel breed,
randomly allocated to 3 groups in high containment throughout the study Vaccine : AFTOVAXPUR DOE trivalent, formulated at low antigen content O Manisa, A22 Iraq, SAT2 Sau

5 Study design G1 (1 mL vaccinated) G2 (controls) G3 (2 mL vaccinated)

6 Study design G1 (1 mL vaccinated) G2 (controls) G3 (2 mL vaccinated)

7 Study design G1 (1 mL vaccinated) G3 (2 mL vaccinated)

8 Study design G1 (1 mL vaccinated) G3 (2 mL vaccinated)

9 Study design Comparisons of G1 and G3 on serological responses
Immunisation serum sample 7 days Comparisons of G1 and G3 on serological responses

10 Study design Immunisation serum sample 7 days

11 Study design Immunisation challenge serum sample clinic + temp.
FMDv O Manisa Immunisation challenge serum sample clinic + temp. blood for virology FMD lesions

12 Results : serology We also regularly took blood samples for
Antibody assays Viraemia testing by RT-PCR

13 Results : serology VNT to FMD A22 Iraq
We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR D28 VNT in G1 statistically non inferior to D28 VNT in G3

14 Results : serology VNT to FMD SAT2
We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR D28 VNT in G1 statistically non inferior to D28 VNT in G3

15 Results : serology VNT to FMD O Manisa
We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR G1 & G2 D28 VNT in G1 statistically inferior to D28 VNT in G3

16 Results : O1 Manisa challenge
Intercurrent Footrot infection during the immunization phase We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

17 Results : O1 Manisa challenge
Rectal temperatures We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

18 Results : O1 Manisa challenge
General Clinical Signs Controls (G2) every animal presented polypnea and lameness between D29 and D31 frequently accompanied or preceded by a reduced feed intake Vaccinates (G1) none of the vaccinates ever presented any general clinical sign We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

19 Results : O1 Manisa challenge
Feet lesions We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR G3 was not challenged !

20 Results : O1 Manisa challenge
Viraemia We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

21 Results : O1 Manisa challenge
G1 (1 mL vaccinated) G2 (controls) We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

22 Results : O1 Manisa challenge
G1 (1 mL vaccinated) G2 (controls) We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR

23 Conclusions The study results demonstrated :
Serological equivalence with a 2 mL dose (A22 Iraq, SAT2 Sau) Clinical and virological protections against a virulent challenge (O Manisa) We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR .

24 WBR : A. Dekker, M. Bleijenberg
Acknowledgements WBR : A. Dekker, M. Bleijenberg Merial B.V. : B. Van Schaijk, J. Coco-Martin Merial S.A.S.: L. Mouton, M. Besset, M. Curet, S. Goutebroze And Technical Staff from the WBR Animal Facilities and MERIAL R&D Lelystad Laboratories We also regularly took blood samples for Antibody assays Viraemia testing by RT-PCR .

25 Thank you

26 Thank you

27 Thank you

28 Thank you

29 Thank you

30 Thank you


Download ppt "Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers."

Similar presentations


Ads by Google